JPIAMR

What JPIAMR does

JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) was an international intergovernmental research coordination initiative that operated from 2011 until it formally ended on May 31, 2025. It served 29 member countries plus the European Commission as a non-voting member, aligning national public investments in antimicrobial resistance (AMR) research through a One Health framework spanning Therapeutics, Diagnostics, Surveillance, Transmission, Environment, and Interventions. Its primary stakeholders were national research funding organisations and government agencies on the funder side, and academic researchers, hospitals, and research institutes on the research-performing side. Over 14 years, JPIAMR coordinated €181.5M of investments across 186 projects and networks, supporting close to 1,900 researchers to collaborate across national and scientific borders.

JPIAMR's core products were coordination and knowledge assets rather than commercial software. The portfolio comprised the AMR Knowledge Hub (an index of AMR research networks, research performing institutes, data platforms, and research funding datahubs), the JPIAMR Project Database, the JPIAMR-VRI Virtual Research Institute for cross-border collaboration, the Strategic Research and Innovation Agenda (SRIA), annual Transnational Calls for joint AMR research projects, a Partner Search Tool for consortium matchmaking, and post-award Reporting and Grant Management workflows. The platform was administered by the JPIAMR Secretariat hosted by the Swedish Research Council (Vetenskapsr\u00e5det) in Stockholm, with EC support via the EXEDRA Coordination and Support Action (2017-2021) and the ERA-NET Cofund JPIAMR-ACTION (2021-2025).

JPIAMR was not a revenue-generating commercial entity. It had no pricing model, no commercial products, and no operational revenue; funding flowed through national government contributions and EC instruments into joint transnational calls and coordination activities. The €181.5M cumulative figure represents research investment deployed to academic projects, not JPIAMR's own top line. As of June 2025, the coordination mandate has been transferred to the successor European Partnership on One Health Antimicrobial Resistance (EUP OHAMR), which brings together 53 organisations from 30 countries and supersedes JPIAMR.

Name

JPIAMR

Legal name

JPIAMR – Joint Programming Initiative on Antimicrobial Resistance

Website

https://jpiamr.eu

Company type

Private

Founded year

2011

Operating status

Closed

Headcount range

11–50 employees

Short description

JPIAMR was an international research coordination initiative that operated from 2011 to May 2025, aligning national AMR research funding across 29 member countries and the European Commission through transnational calls, a knowledge hub, and a virtual research platform.

Ownership category

akta.pro rank

Product category

International Research Funding Coordination

NAICS

Scientific Research and Development Services (5417)

SIC

Foreign Governments (8888)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Global Health Security & Pandemic Preparedness Partnerships (HLAJAOAH), International & Global Public Health Aid Administration (Government Donors) (HLAJALAO)

Keywords

• Transnational research coordination
• Antimicrobial resistance research
• Collaborative research funding
• One Health AMR platform
• Public health research funding

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels8 records

Core offering

JPIAMR coordinated transnational antimicrobial resistance (AMR) research funding and collaboration across 29 member countries and the European Commission through a One Health approach. It issued competitive joint calls for transnational research projects (e.g., AMR Interventions 2024 call: 13 projects, 64 partners, 15 countries, €17.2M), aligned national research strategies via the Strategic Research and Innovation Agenda (SRIA), and provided knowledge resources through the AMR Knowledge Hub, Project Database, and JPIAMR-VRI virtual research institute. Total cumulative investment reached €181.5M across 186 projects and networks supporting close to 1,900 researchers.

Product overview

JPIAMR is an international research coordination platform, not a traditional software product company. It operates as a collaborative funding and coordination mechanism engaging 29 nations and the European Commission to curb antimicrobial resistance through a One Health approach. The platform offers a portfolio of coordination services including: a Project Database for discovering funded AMR research, an AMR Knowledge Hub providing access to data platforms and research infrastructure resources, the JPIAMR-VRI for virtual research collaboration, Transnational Calls for funding collaborative research projects, Project Resources including publications and tools from funded research, Partner Search Tools for consortium formation, and Grant Management Systems for post-award reporting and changes. The platform is succeeded by the European Partnership on One Health AMR (EUP OHAMR) as of June 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• JPIAMR Project Database Comprehensive database of JPIAMR-supported AMR research projects and networks, enabling researchers and stakeholders to discover and access funded research across 29 member countries.
• AMR Knowledge Hub Collection of resources on AMR research networks, research performing institutes and centres, AMR data platforms, a research funding datahub, and research infrastructure platforms, accessible to the AMR research community.
• JPIAMR-VRI (Virtual Research Institute) Virtual Research Institute supporting and coordinating AMR research collaboration across member countries and disciplines under a One Health framework.
• JPIAMR Transnational Calls Annual competitive transnational calls for collaborative AMR research projects and networks, funding cross-country research across Therapeutics, Diagnostics, Surveillance, Transmission, Environment, and Interventions priority areas.
• Project Resources Curated collection of research publications and project tools produced by researchers funded under various JPIAMR transnational calls.
• Partner Search Tool Match-making tool facilitating networking and creation of cross-country research consortia for JPIAMR funding calls.
• Reporting and Grant Management System Post-award processes including scientific report submission templates (mid-term and final reports) for funded research projects and networks, with ex-post evaluation procedures.
• Grant Change Request System Procedures and forms for requesting changes to ongoing grants including tenure extensions, change of affiliation, coordinator/partner changes, and workplan modifications.
• Strategic Research and Innovation Agenda (SRIA) Comprehensive framework document outlining six key priority topics (Therapeutics, Diagnostics, Surveillance, Transmission, Environment, and Interventions) and research objectives for AMR research prioritisation and alignment of national research strategies.

Quantifiable outcome

• €181.5M invested in AMR research across 186 projects and networks involving 29 countries
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• EU-JAMRAI (European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections): EU-funded joint action coordinating AMR policy and healthcare-associated infection response across EU member states. Comparable in multi-country AMR coordination mandate but focused on policy/implementation rather than research funding.
• ReAct – Action on Antibiotic Resistance: International network advocating for action on antibiotic resistance, with research policy and convening roles. Comparable in global AMR network orientation, though focused on advocacy rather than R&D funding.

Broad incumbents

• Innovative Health Initiative (IHI / formerly IMI): Large-scale public-private partnership funding health research across multiple therapeutic areas. Comparable in being a multi-country, multi-funder health R&D coordination platform but much broader in scope than AMR.
• Wellcome Trust: Major charitable foundation funding AMR and other global health R&D. Comparable as a significant AMR research funder with global reach, though operating as a single foundation rather than a multi-country coordination body.

Direct peers

• AMR Action Fund: Venture-style fund backed by pharma companies, the Wellcome Trust, and the EIB to invest in clinical-stage antibiotic developers. Comparable in AMR focus but operates a private investment model rather than grant coordination.
• CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator): Global non-profit partnership that accelerates antibacterial R&D by funding early-stage research and product developers. Comparable to JPIAMR as a transnational AMR R&D funding mechanism, with a portfolio-company accelerator model.
• EDCTP (Global Health EDCTP3 Joint Undertaking / Global Health EDCTP): European-African partnership funding clinical research on poverty-related infectious diseases. Highly comparable in structure (multi-country research coordination platform) and mission-adjacent to JPIAMR's AMR Therapeutics/Diagnostics priorities.
• Global Antibiotic R&D Partnership (GARDP): International R&D partnership developing new antibiotic treatments, particularly for drug-resistant infections. Highly comparable to JPIAMR in mission (AMR-focused) and structure (multi-country, multi-funder), with a more product-development orientation.
• European Partnership on One Health AMR (EUP OHAMR): Direct successor to JPIAMR, launched June 2025 with 53 organisations from 30 countries. Operates the same One Health AMR research coordination mandate, inheriting the SRIA, VRI, and Knowledge Hub.

Others

• BARDA (Biomedical Advanced Research and Development Authority): US government authority that funds advanced development of medical countermeasures, including AMR. Comparable as a major AMR R&D funder but operates as a single government agency rather than a multi-country coordination platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jpiamr
• YouTubeyoutube.com/channel/UC9TXetkVWUbCgM4fn2iNZ9A
• Facebookfacebook.com/JPIAMR
• LinkedInlinkedin.com/company/jpiamr

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JPIAMR